Blood cancer (Chronic lymphocytic leukemia)
Manufactured under WHO-GMP compliant processes at our US FDA approved facility in Baddi, Himachal Pradesh.
Rigorous quality control at every stage ensures reliable purity and potency across every batch produced.
Trusted by pharmaceutical partners and distributors across 90+ countries worldwide.
Ibrutinib is a potent and irreversible inhibitor of Bruton's tyrosine kinase (BTK), an integral component of the B-cell receptor (BCR) and cytokine receptor pathways. Constitutive activation of B-cell receptor signaling is important for survival of malignant B-cells; BTK inhibition results in decreased malignant B-cell proliferation and survival.